EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

NCT02859077 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: EGFR-TKI
DRUG: Chemotherapy（pemetrexed/gemcitabine）
DRUG: Chemotherapy（carboplatin）

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China